Clinical material technology development and pilot manufacturing
Active Awarded
- Contract number
- 75N91026F00032
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $17,712,309
Award facts
- Contract value 100% obligated
- $17,712,309.00 Current and potential, with all options
- Completion date 2% complete
- Current and potential, with all options
- Funding agency
- National Institute of Allergy and Infectious Diseases National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this award
The National Institute of Allergy and Infectious Diseases issued a delivery order to Leidos Biomedical Research Inc. on September 24, 2026, with a ceiling value of $17.7 million for clinical material technology development and pilot manufacturing.
Leidos Biomedical Research operates the Frederick National Laboratory for Cancer Research as a Federally Funded Research and Development Center (FFRDC) for the National Cancer Institute and performs biomedical research execution, facilities infrastructure, clinical trial support, and specialized manufacturing under cost-plus-fixed-fee delivery orders from master indefinite delivery vehicles with NCI and NIAID. Place of performance is Frederick, Maryland. Ultimate completion is September 23, 2031. The order focuses on manufacturing platforms for monoclonal antibodies, gene therapy vectors, vaccine technology, and chemistry, manufacturing, and controls support for therapeutic candidates. Leidos Biomedical Research competes exclusively in full-and-open procurement; as an FFRDC, it is structurally barred from SBA set-asides.
Quick answers
Who was awarded contract 75N91026F00032?
75N91026F00032 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 24, 2026.
How much is contract 75N91026F00032 worth?
The government has obligated $17,712,309 on 75N91026F00032.
Which agency awarded contract 75N91026F00032?
National Cancer Institute (National Institutes of Health) awarded 75N91026F00032, with funding from National Institute of Allergy and Infectious Diseases (National Institutes of Health).
Is contract 75N91026F00032 an order under another contract?
Yes. 75N91026F00032 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91026F00032 competed?
The extent of competition for 75N91026F00032 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award